Ulcerative Colitis – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Ulcerative Colitis – Pipeline Review, H2 2017’, provides an overview of the Ulcerative Colitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ulcerative Colitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ulcerative Colitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Ulcerative Colitis

The report reviews pipeline therapeutics for Ulcerative Colitis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Ulcerative Colitis therapeutics and enlists all their major and minor projects

The report assesses Ulcerative Colitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Ulcerative Colitis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Ulcerative Colitis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Ulcerative Colitis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4D Pharma PLC

AbbVie Inc

AbGenomics International Inc

Abivax SA

Adello Biologics LLC

Aerpio Therapeutics Inc

Akebia Therapeutics Inc

Allergan Plc

Am-Pharma BV

Amgen Inc

Aptevo Therapeutics Inc

Arena Pharmaceuticals Inc

Atlantic Bio Sci LLC

Atlantic Healthcare Plc

Blueberry Therapeutics Ltd

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Celgene Corp

Celltrion Inc

ChemoCentryx Inc

ChironWells GmbH

Coherus BioSciences Inc

Cosmo Pharmaceuticals NV

Dr. August Wolff GmbH & Co KG Arzneimittle

EA Pharma Co Ltd

Eli Lilly and Co

Enceladus Pharmaceuticals BV

Enterome Bioscience SA

Ferring International Center SA

Fresenius SE & Co KGaA

Galapagos NV

Genentech Inc

Genor BioPharma Co Ltd

GlaxoSmithKline Plc

iCo Therapeutics Inc.

Inception Sciences Inc

InDex Pharmaceuticals Holding AB

Innovate Biopharmaceuticals Inc

Intas Pharmaceuticals Ltd

Ironwood Pharmaceuticals Inc

Istesso Ltd

Johnson & Johnson

Kaken Pharmaceutical Co Ltd

Keystone Biologics Inc

Kyowa Hakko Kirin Co Ltd

LG Chem Ltd

LIPID THERAPEUTICS GmbH

Lycera Corp

Medestea Research & Production SpA

Merck & Co Inc

Miyarisan Pharmaceutical Company Ltd

Morphotek Inc

Ogeda SA

Oncobiologics Inc

OSE Immunotherapeutics

Pfizer Inc

Principia Biopharma Inc

Protab Ltd

Protagonist Therapeutics Inc

Protalix BioTherapeutics Inc

Qu Biologics Inc

Re-Pharm Ltd

Rebiotix Inc

RedHill Biopharma Ltd

Reliance Life Sciences Pvt Ltd

Sareum Holdings Plc

Seres Therapeutics Inc

Shire Plc

Sigmoid Pharma Ltd

Stelic Institute & Co Inc

Sterna biologicals Gmbh & Co KG

Synergy Pharmaceuticals Inc

Synlogic Inc

Takeda Pharmaceutical Co Ltd

Theravance Biopharma Inc

Thetis Pharmaceuticals LLC

Tillotts Pharma AG

TopiVert Ltd

TTY Biopharm Company Ltd

UCB SA

Ventria Bioscience

Vivelix Pharmaceuticals Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Ulcerative Colitis - Overview 7

Ulcerative Colitis - Therapeutics Development 8

Ulcerative Colitis - Therapeutics Assessment 27

Ulcerative Colitis - Companies Involved in Therapeutics Development 41

Ulcerative Colitis - Drug Profiles 83

Ulcerative Colitis - Dormant Projects 397

Ulcerative Colitis - Discontinued Products 404

Ulcerative Colitis - Product Development Milestones 406

Appendix 416

List of Tables

List of Tables

Number of Products under Development for Ulcerative Colitis, H2 2017 24

Number of Products under Development by Companies, H2 2017 26

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 27

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 28

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017 29

Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017 30

Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017 31

Number of Products under Development by Universities/Institutes, H2 2017 32

Products under Development by Companies, H2 2017 33

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 34

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 35

Products under Development by Companies, H2 2017 (Contd..3), H2 2017 36

Products under Development by Companies, H2 2017 (Contd..4), H2 2017 37

Products under Development by Companies, H2 2017 (Contd..5), H2 2017 38

Products under Development by Companies, H2 2017 (Contd..6), H2 2017 39

Products under Development by Companies, H2 2017 (Contd..7), H2 2017 40

Products under Development by Companies, H2 2017 (Contd..8), H2 2017 41

Products under Development by Universities/Institutes, H2 2017 42

Number of Products by Stage and Target, H2 2017 44

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 45

Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017 46

Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017 47

Number of Products by Stage and Mechanism of Action, H2 2017 49

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 50

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017 51

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017 52

Number of Products by Stage and Route of Administration, H2 2017 54

Number of Products by Stage and Molecule Type, H2 2017 56

Ulcerative Colitis – Pipeline by 4D Pharma PLC, H2 2017 57

Ulcerative Colitis – Pipeline by AbbVie Inc, H2 2017 57

Ulcerative Colitis – Pipeline by AbGenomics International Inc, H2 2017 58

Ulcerative Colitis – Pipeline by Abivax SA, H2 2017 58

Ulcerative Colitis – Pipeline by Adello Biologics LLC, H2 2017 59

Ulcerative Colitis – Pipeline by Aerpio Therapeutics Inc, H2 2017 59

Ulcerative Colitis – Pipeline by Akebia Therapeutics Inc, H2 2017 60

Ulcerative Colitis – Pipeline by Allergan Plc, H2 2017 60

Ulcerative Colitis – Pipeline by Am-Pharma BV, H2 2017 61

Ulcerative Colitis – Pipeline by Amgen Inc, H2 2017 61

Ulcerative Colitis – Pipeline by Aptevo Therapeutics Inc, H2 2017 62

Ulcerative Colitis – Pipeline by Arena Pharmaceuticals Inc, H2 2017 62

Ulcerative Colitis – Pipeline by Atlantic Bio Sci LLC, H2 2017 63

Ulcerative Colitis – Pipeline by Atlantic Healthcare Plc, H2 2017 63

Ulcerative Colitis – Pipeline by Blueberry Therapeutics Ltd, H2 2017 64

Ulcerative Colitis – Pipeline by Boehringer Ingelheim GmbH, H2 2017 64

Ulcerative Colitis – Pipeline by Bristol-Myers Squibb Co, H2 2017 65

Ulcerative Colitis – Pipeline by Celgene Corp, H2 2017 66

Ulcerative Colitis – Pipeline by Celltrion Inc, H2 2017 67

Ulcerative Colitis – Pipeline by ChemoCentryx Inc, H2 2017 67

Ulcerative Colitis – Pipeline by ChironWells GmbH, H2 2017 68

Ulcerative Colitis – Pipeline by Coherus BioSciences Inc, H2 2017 68

Ulcerative Colitis – Pipeline by Cosmo Pharmaceuticals NV, H2 2017 69

Ulcerative Colitis – Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittle, H2 2017 69

Ulcerative Colitis – Pipeline by EA Pharma Co Ltd, H2 2017 70

Ulcerative Colitis – Pipeline by Eli Lilly and Co, H2 2017 70

Ulcerative Colitis – Pipeline by Enceladus Pharmaceuticals BV, H2 2017 71

Ulcerative Colitis – Pipeline by Enterome Bioscience SA, H2 2017 71

Ulcerative Colitis – Pipeline by Ferring International Center SA, H2 2017 72

Ulcerative Colitis – Pipeline by Fresenius SE & Co KGaA, H2 2017 72

Ulcerative Colitis – Pipeline by Galapagos NV, H2 2017 73

Ulcerative Colitis – Pipeline by Genentech Inc, H2 2017 73

Ulcerative Colitis – Pipeline by Genor BioPharma Co Ltd, H2 2017 74

Ulcerative Colitis – Pipeline by GlaxoSmithKline Plc, H2 2017 74

Ulcerative Colitis – Pipeline by iCo Therapeutics Inc., H2 2017 75

Ulcerative Colitis – Pipeline by Inception Sciences Inc, H2 2017 75

Ulcerative Colitis – Pipeline by InDex Pharmaceuticals Holding AB, H2 2017 76

Ulcerative Colitis – Pipeline by Innovate Biopharmaceuticals Inc, H2 2017 76

Ulcerative Colitis – Pipeline by Intas Pharmaceuticals Ltd, H2 2017 77

Ulcerative Colitis – Pipeline by Ironwood Pharmaceuticals Inc, H2 2017 77

Ulcerative Colitis – Pipeline by Istesso Ltd, H2 2017 78

Ulcerative Colitis – Pipeline by Johnson & Johnson, H2 2017 78

Ulcerative Colitis – Pipeline by Kaken Pharmaceutical Co Ltd, H2 2017 79

Ulcerative Colitis – Pipeline by Keystone Biologics Inc, H2 2017 79

Ulcerative Colitis – Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017 80

Ulcerative Colitis – Pipeline by LG Chem Ltd, H2 2017 81

Ulcerative Colitis – Pipeline by LIPID THERAPEUTICS GmbH, H2 2017 81

Ulcerative Colitis – Pipeline by Lycera Corp, H2 2017 82

Ulcerative Colitis – Pipeline by Medestea Research & Production SpA, H2 2017 82

Ulcerative Colitis – Pipeline by Merck & Co Inc, H2 2017 83

Ulcerative Colitis – Pipeline by Miyarisan Pharmaceutical Company Ltd, H2 2017 83

Ulcerative Colitis – Pipeline by Morphotek Inc, H2 2017 84

Ulcerative Colitis – Pipeline by Ogeda SA, H2 2017 84

Ulcerative Colitis – Pipeline by Oncobiologics Inc, H2 2017 85

Ulcerative Colitis – Pipeline by OSE Immunotherapeutics, H2 2017 85

Ulcerative Colitis – Pipeline by Pfizer Inc, H2 2017 86

Ulcerative Colitis – Pipeline by Principia Biopharma Inc, H2 2017 86

Ulcerative Colitis – Pipeline by Protab Ltd, H2 2017 87

Ulcerative Colitis – Pipeline by Protagonist Therapeutics Inc, H2 2017 87

Ulcerative Colitis – Pipeline by Protalix BioTherapeutics Inc, H2 2017 88

Ulcerative Colitis – Pipeline by Qu Biologics Inc, H2 2017 88

Ulcerative Colitis – Pipeline by Re-Pharm Ltd, H2 2017 89

Ulcerative Colitis – Pipeline by Rebiotix Inc, H2 2017 89

Ulcerative Colitis – Pipeline by RedHill Biopharma Ltd, H2 2017 90

Ulcerative Colitis – Pipeline by Reliance Life Sciences Pvt Ltd, H2 2017 90

Ulcerative Colitis – Pipeline by Sareum Holdings Plc, H2 2017 91

Ulcerative Colitis – Pipeline by Seres Therapeutics Inc, H2 2017 91

Ulcerative Colitis – Pipeline by Shire Plc, H2 2017 92

Ulcerative Colitis – Pipeline by Sigmoid Pharma Ltd, H2 2017 92

Ulcerative Colitis – Pipeline by Stelic Institute & Co Inc, H2 2017 93

Ulcerative Colitis – Pipeline by sterna biologicals Gmbh & Co KG, H2 2017 93

Ulcerative Colitis – Pipeline by Synergy Pharmaceuticals Inc, H2 2017 93

Ulcerative Colitis – Pipeline by Synlogic Inc, H2 2017 94

Ulcerative Colitis – Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017 94

Ulcerative Colitis – Pipeline by Theravance Biopharma Inc, H2 2017 95

Ulcerative Colitis – Pipeline by Thetis Pharmaceuticals LLC, H2 2017 95

Ulcerative Colitis – Pipeline by Tillotts Pharma AG, H2 2017 96

Ulcerative Colitis – Pipeline by TopiVert Ltd, H2 2017 96

Ulcerative Colitis – Pipeline by TTY Biopharm Company Ltd, H2 2017 97

Ulcerative Colitis – Pipeline by UCB SA, H2 2017 97

Ulcerative Colitis – Pipeline by Ventria Bioscience, H2 2017 98

Ulcerative Colitis – Pipeline by Vivelix Pharmaceuticals Ltd, H2 2017 98

Ulcerative Colitis – Dormant Projects, H2 2017 413

Ulcerative Colitis – Dormant Projects, H2 2017 (Contd..1), H2 2017 414

Ulcerative Colitis – Dormant Projects, H2 2017 (Contd..2), H2 2017 415

Ulcerative Colitis – Dormant Projects, H2 2017 (Contd..3), H2 2017 416

Ulcerative Colitis – Dormant Projects, H2 2017 (Contd..4), H2 2017 417

Ulcerative Colitis – Dormant Projects, H2 2017 (Contd..5), H2 2017 418

Ulcerative Colitis – Dormant Projects, H2 2017 (Contd..6), H2 2017 419

Ulcerative Colitis – Discontinued Products, H2 2017 420

Ulcerative Colitis – Discontinued Products, H2 2017 (Contd..1), H2 2017 421

List of Figures

List of Figures

Number of Products under Development for Ulcerative Colitis, H2 2017 24

Number of Products under Development by Companies, H2 2017 25

Number of Products under Development by Universities/Institutes, H2 2017 32

Number of Products by Top 10 Targets, H2 2017 43

Number of Products by Stage and Top 10 Targets, H2 2017 43

Number of Products by Top 10 Mechanism of Actions, H2 2017 48

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 48

Number of Products by Routes of Administration, H2 2017 53

Number of Products by Stage and Routes of Administration, H2 2017 53

Number of Products by Top 10 Molecule Types, H2 2017 55

Number of Products by Stage and Top 10 Molecule Types, H2 2017 55

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports